The efficacy of measurement of the serum beta-d glucan in the patients with biliary atresia

Sanada, Yukihiro; Mizuta, Koichi; Urahashi, Taizen; Ihara, Yoshiyuki; Wakiya, Taiichi; Okada, Noriki; Yamada, Naoya; Yasuda, Yoshikazu; Kawarasaki, Hideo

doi:10.1007/s00383-012-3166-7

Cited by 5 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human clinical conditions which result in reduced hepatic function have been shown to be associated with elevated serum BDG. Sanada et al 2014 have described the relationship between serum BDG levels in the setting of pediatric end stage liver disease [103]. The liver clearance function was underscored by significantly higher BDG titers in portal blood relative to the peripheral circulation.…”

Section: Hepatic Functionmentioning

confidence: 99%

Specificity Influences in (1→3)-β-d-Glucan-Supported Diagnosis of Invasive Fungal Disease

Finkelman

2020

JoF

View full text Add to dashboard Cite

(1→3)-β-glucan (BDG) testing as an adjunct in the diagnosis of invasive fungal disease (IFD) has been in use for nearly three decades. While BDG has a very high negative predictive value in this setting, diagnostic false positives may occur, limiting specificity and positive predictive value. Although results may be diagnostically false positive, they are analytically correct, due to the presence of BDG in the circulation. This review surveys the non-IFD causes of elevated circulating BDG. These are in the main, iatrogenic patient contamination through the use of BDG-containing medical devices and parenterally-delivered materials as well as translocation of intestinal luminal BDG due to mucosal barrier injury. Additionally, infection with Nocardia sp. may also contribute to elevated circulating BDG. Knowledge of the factors which may contribute to such non-IFD-related test results can improve the planning and interpretation of BDG assays and permit investigational strategies, such as serial sampling and BDG clearance evaluation, to assess the likelihood of contamination and improve patient care.

show abstract

Section: Hepatic Functionmentioning

confidence: 99%

Specificity Influences in (1→3)-β-d-Glucan-Supported Diagnosis of Invasive Fungal Disease

Finkelman

2020

JoF

View full text Add to dashboard Cite

show abstract

“…There have been few publications on the utility (1→3)-β- d -glucan testing to detect invasive fungal disease in at risk children. The studies that have been published have primarily been limited to case reports or small patient numbers [ 52 , 53 , 56 , 57 , 58 , 59 , 60 , 61 , 62 ]. A Chinese study evaluated surveillance (1→3)-β- d -glucan testing in 130 pediatric patients using a non-commercial assay.…”

Section: Diagnosis Of Pediatric Candidiasismentioning

confidence: 99%

Pediatric Invasive Candidiasis: Epidemiology and Diagnosis in Children

Steinbach

2016

JoF

View full text Add to dashboard Cite

Pediatric patients present with differing underlying conditions and cytotoxic therapeutic protocols, so the differing epidemiology of invasive candidiasis in children versus adults is not surprising. Understanding the Candida species epidemiology is critical, as we often begin empiric therapy or therapy before antifungal susceptibilities are known. Reports with newer molecular diagnostic assays for invasive candidiasis are rare and require more study to develop firm pediatric-specific guidance. Antifungal treatment of pediatric candidiasis is reviewed in the context of larger epidemiologic studies and the few trials completed to date.

show abstract

“…Beta‐glucan levels are elevated in murine models of Clostridium difficile infection with associated increased gastrointestinal permeability . Beta‐glucan is also cleared by the RES, including Kupffer cells, and has been shown to be a useful marker of RES function in a cohort of pediatric patients with biliary atresia .…”

Section: Beta‐glucan and Inflammation In End‐stage Kidney Diseasementioning

confidence: 99%

Unexplained inflammation in end‐stage kidney disease: Is the combination of enhanced gastrointestinal permeability and reticuloendothelial dysfunction its cause?

Swift

Farrington

2019

Seminars in Dialysis

View full text Add to dashboard Cite

Unexplained chronic inflammation is prevalent in end‐stage kidney disease, and contributes toward accelerated cardiovascular disease, and premature death. The source of inflammation is unclear, although increased gastrointestinal permeability is a likely contributory factor. Whether a “leaky” gut leads to penetration of the systemic circulation by gut‐derived pathogens is at least partly dependent on Kupffer cell function. These resident liver macrophages are an important part of the reticuloendothelial system (RES), and there is evidence for Kupffer cell and reticuloendothelial dysfunction in chronic kidney disease. These observations are compatible with the inflammatory milieu of chronic kidney disease being of gut origin. Measuring gut permeability in chronic kidney disease is challenging. Use of fecal biomarkers and other novel serum biomarkers represent potential alternative tools. One such marker is (1‐3)‐Beta‐D‐glucan, a polysaccharide constituent of many fungal, bacterial, and plant cell walls; levels of (1‐3)‐Beta‐D‐glucan are elevated in hemodialysis patients. Gastrointestinal permeability and impaired removal by the RES may contribute to these high levels, suggesting potential importance as a biomarker. High levels of (1‐3)‐Beta‐D‐glucan also falsely elevate endotoxin measurements. Measuring the contribution of gastrointestinal permeability and RES dysfunction to systemic inflammation may be an important step in designing therapies to reduce systemic inflammation in chronic kidney disease.

show abstract

The efficacy of measurement of the serum beta-d glucan in the patients with biliary atresia

Abstract: The serum BDG can be used as a biological index in place of liver metabolism and should be measured in BA patients as a non-invasive indicator of the degree of progression of liver failure.

Cited by 5 publications

References 13 publications

Specificity Influences in (1→3)-β-d-Glucan-Supported Diagnosis of Invasive Fungal Disease

Specificity Influences in (1→3)-β-d-Glucan-Supported Diagnosis of Invasive Fungal Disease

Pediatric Invasive Candidiasis: Epidemiology and Diagnosis in Children

Unexplained inflammation in end‐stage kidney disease: Is the combination of enhanced gastrointestinal permeability and reticuloendothelial dysfunction its cause?

Contact Info

Product

Resources

About